MEGGLE highlighting co-processed lactoses at long awaited CPhI China 2023

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE is returning to the huge annual CPHI China expo in Shanghai as a prominent exhibitor.

MEGGLE has welcomed the return of the event following a three year gap due to the Covid pandemic.

Focus on co-processed excipients

As in its previous appearance in 2019, MEGGLE will exhibit in partnership with its local agents, Guangzhou Standard Pharma Ltd. and Shanghai Pintech Pharmaceutical Co. Their 56 square meter stand at Booth E4D20 at the Shanghai New International Expo Center (SNIEC) will feature the huge range of MEGGLE added value lactose based excipients.

This year’s display will particularly highlight the benefits of MEGGLE’s co-processed lactose products, such as  Cellactose® 80,  MicroceLac® 100,  StarLac® and CombiLac®,  that have particular advantages in processes like direct compression tablet manufacturing.

MEGGLE will also be a prominent presence on the WeChat official networking site that supports CPHI China.

About MEGGLE

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About CPhI China 2023

Since 2000, CPhI China has established itself as the leading pharma industry business and sourcing event for Eastern Asia, reflecting the huge growth of the Chinese pharma market.

CPhI China 2023 is a three-day event opening June 19 at the Shanghai New International Exhibition Center (SNIEC) and is co-located with the  P-Mec machinery and equipment show. Together, the shows bring together some 3,000 suppliers, attracting around 45,000 visits from more than 100 countries. In addition, the rebranded CPHI China has now become a hybrid event with an online dimension.

CPhI China is organized by Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (IM Sinoexpo) with further information at http://www.cphi-china.cn/en

Resources

Click on MEGGLE at CPhI China 2023 to see exhibitor profile.